骨肉瘤与活化B淋巴细胞融合株的建立及其体内外生物学特性  

Fusion of a Murine Osteosarcoma LM_9 with Activalted B Lymphocyte and the Biocharacteristics of Fused Tumor Cells

作　　者：彭磊[1] 肖毅[1] 孟国林[1] 吴银松[1] 许诺[1] 张志培[1] 王臻[1] 王庆良[1] 

机构地区：[1]第四军医大学西京医院骨科,西安710032

出　　处：《中国矫形外科杂志》2001年第6期573-575,共3页Orthopedic Journal of China

基　　金：国家自然科学基金资助! (编号 397770 4 9)

摘　　要：目的 :建立骨肉瘤与活化B淋巴细胞融合的肿瘤疫苗 ,探讨其方法及其生物学特性。方法 :以 5 0 %PEG为融合剂 ,将C3h小鼠来源的HGRPT基因缺陷型LM9骨肉瘤细胞与LPS活化的C3h小鼠B淋巴细胞进行融合。经HAT选择性培养基筛选后 ,再观察该融合瘤株的体内外生长特性及对C3h小鼠的致瘤性。结果 :该融合瘤株体外生长缓慢 ,对C3h小鼠无致瘤性 ,与LM9细胞有较大差别。结论 :与活化B淋巴细胞融合 ,骨肉瘤细胞可能改变其生物学特性 。Objective: To set up osteosarcoma vaccine by the LM 9 osteosarcoma derived from C 3h mice fused with activated B cells. Study the method and fusion cell biocharacteristics.Method:The LM 9 osteosarcoma derived fron C 3h mice was fused with LPS activated B cells by using 50% PEG.The fused cells were selected by HAT medium and cultured in vitro.Result:In contrast to LM 9 the fused cells grew significantly slow in vivo and invitrol,without oncogenic character. Conclusion:It is possible that the LM 9 osteosarcoma biology characteristics change after fusing with LPS activated B cells,which indicated the decreased tumorigenicety of tumor.

关 键 词：LM9骨肉瘤 B淋巴细胞 细胞融合 

分 类 号：R738.1[医药卫生—肿瘤]